OnkoSight AdvancedTM Features
GenPath®’s scientific team has developed OnkoSight AdvancedTM, a proprietary product line of next-generation sequencing assays for solid tumors and hematologic malignancies that focuses on actionable genomic variants in common cancers. Clinicians can opt for a focused panel based on medical necessity, concentrating on actionable alterations in prevalent cancers, or a broader, more comprehensive panel. Our commitment is not only to deliver high-quality testing but also to address common challenges such as Turnaround Time (TAT) and Quantity Not Sufficient (QNS) rates.
KEY ADVANTAGES:
High Clinical Utility
Targeted, tumor-specific, and comprehensive NGS panels based on medical necessity inclusive of guideline-recommended genes and biomarkers for use with FDA-approved therapies, and those with established disease associations for which there are clinical trial options.
Industry-leading Turnaround Time
OnkoSight AdvancedTM provides actionable results as fast as 3 days* from receipt of the specimen at the laboratory for timely initiation of medical management.
Minimal DNA Requirement
OnkoSight AdvancedTM effectively utilize tumor samples. The DNA input requirement for OnkoSight AdvancedTM (40ng) is approximately half that of other commercially available NGS assays employing similar hybrid capture NGS technology, and utilizing unique molecular indices to reduce sequencing error by up to 10-20 fold.
Cost Effective
Optimize efficiency and provide significant cost savings over similar tests in the market.
Customized NGS Reporting
Clinicopathologic data is routinely factored into final interpretations for all detected variants, providing tailored, patient-specific reports. Reporting of detected variants includes therapeutic associations with FDA-approved therapies and is reported and classified following AMP/ASCO/CAP recommendations.
*Reporting times are typical and begin once the specimen is received at the laboratory but could be extended in situations outside GenPath’s reasonable control.